{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T18:50:03Z","timestamp":1785783003234,"version":"3.56.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jchf.2026.102999","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T05:17:02Z","timestamp":1772860622000},"page":"102999","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Empagliflozin in De Novo vs Acute Decompensated Chronic Heart Failure"],"prefix":"10.1016","volume":"14","author":[{"given":"Christiane E.","family":"Angermann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Gerhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan P.","family":"Blatchford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9977-7722","authenticated-orcid":false,"given":"Jan","family":"Biegus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean P.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail","family":"Kosiborod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2304-6138","authenticated-orcid":false,"given":"Joao Pedro","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Nassif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell A.","family":"Psotka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasper","family":"Tromp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina J.","family":"Kraus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Ponikowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Teerlink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriaan A.","family":"Voors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchf.2026.102999_bib1","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41572-020-0151-7","article-title":"Acute heart failure","volume":"6","author":"Arrigo","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jchf.2026.102999_bib2","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1016\/j.jacc.2017.04.043","article-title":"Hospitalization for recently diagnosed versus worsening chronic heart failure: from the ASCEND-HF trial","volume":"69","author":"Greene","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2026.102999_bib3","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1002\/ejhf.1800","article-title":"Readmission and death in patients admitted with new-onset versus worsening of chronic heart failure: insights from a nationwide cohort","volume":"22","author":"Butt","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2026.102999_bib4","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1080\/00015385.2020.1747178","article-title":"Differences in clinical characteristics and outcome of de novo heart failure compared to acutely decompensated chronic heart failure - systematic review and meta-analysis","volume":"76","author":"Pranata","year":"2021","journal-title":"Acta Cardiol"},{"key":"10.1016\/j.jchf.2026.102999_bib5","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s10741-019-09894-y","article-title":"Acutely decompensated versus acute heart failure: two different entities","volume":"25","author":"Xanthopoulos","year":"2020","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.jchf.2026.102999_bib6","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.3390\/biom11111701","article-title":"Differences in the biomarker profile of de novo acute heart failure versus decompensation of chronic heart failure","volume":"11","author":"Nawrocka-Millward","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.jchf.2026.102999_bib7","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2026.102999_bib8","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2026.102999_bib9","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1002\/ejhf.1844","article-title":"The real world of de novo heart failure: the next frontier for heart failure clinical trials?","volume":"22","author":"Khan","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2026.102999_bib10","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jchf.2026.102999_bib11","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial","volume":"28","author":"Voors","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jchf.2026.102999_bib12","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1038\/s41591-022-01971-4","article-title":"Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER","volume":"28","author":"Jhund","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jchf.2026.102999_bib13","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1093\/eurheartj\/ehab798","article-title":"Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction","volume":"43","author":"Butler","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2026.102999_bib14","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.jchf.2026.102999_bib15","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2026.102999_bib16","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/ejhf.2137","article-title":"Sodium\u2013glucose co-transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial","volume":"23","author":"Tromp","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2026.102999_bib17","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/ejhf.2853","article-title":"The win ratio method in heart failure trials: lessons learnt from EMPULSE","volume":"25","author":"Pocock","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2026.102999_bib18","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/eurheartj\/ehac530","article-title":"Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial","volume":"44","author":"Biegus","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2026.102999_bib19","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1093\/eurheartj\/ehu065","article-title":"Diuretic response in acute heart failure: clinical characteristics and prognostic significance","volume":"35","author":"Valente","year":"2014","journal-title":"Eur Heart J"},{"issue":"20","key":"10.1016\/j.jchf.2026.102999_bib20","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1161\/CIRCULATIONAHA.125.076575","article-title":"Dapagliflozin in patients hospitalized for heart failure: primary results of the DAPA ACT HF-TIMI 68 randomized clinical trial and meta-analysis of sodium-glucose cotransporter-2 inhibitors in patients hospitalized for heart failure","volume":"152","author":"Berg","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2026.102999_bib21","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","article-title":"Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial","volume":"400","author":"Mebazaa","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jchf.2026.102999_bib22","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1002\/ejhf.2852","article-title":"The blunted loop diuretic response in acute heart failure is driven by reduced tubular responsiveness rather than insufficient tubular delivery. The role of furosemide urine excretion on diuretic and natriuretic response in acute heart failure","volume":"25","author":"Biegus","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2026.102999_bib23","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/s41598-024-51744-x","article-title":"Spot urine sodium as a marker of urine dilution and decongestive abilities in acute heart failure","volume":"14","author":"Guzik","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.jchf.2026.102999_bib24","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jchf.2023.06.036","article-title":"Efficacy and safety of empagliflozin according to background diuretic use in HFrEF: post-hoc analysis of EMPEROR-Reduced","volume":"12","author":"Dhingra","year":"2024","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jchf.2026.102999_bib25","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1161\/CIRCHEARTFAILURE.113.000895","article-title":"Loop diuretic efficiency: a metric of diuretic responsiveness with prognostic importance in acute decompensated heart failure","volume":"7","author":"Testani","year":"2014","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2026.102999_bib26","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/ejhf.170","article-title":"Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcome--an analysis from RELAX-AHF","volume":"16","author":"Voors","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2026.102999_bib27","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1002\/ejhf.2681","article-title":"Renal effects of empagliflozin in patients hospitalized for acute heart failure: from the EMPULSE trial","volume":"24","author":"Voors","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2026.102999_bib28","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.122.061732","article-title":"Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling\/autophagy hypothesis","volume":"146","author":"Packer","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2026.102999_bib29","doi-asserted-by":"crossref","first-page":"C525","DOI":"10.1152\/ajpcell.00143.2024","article-title":"Mechanisms of heart failure and chronic kidney disease protection by SGLT2 inhibitors in nondiabetic conditions","volume":"327","author":"Girardi","year":"2024","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.jchf.2026.102999_bib30","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/j.jacc.2024.07.013","article-title":"Reaffirmation of mechanistic proteomic signatures accompanying SGLT2 inhibition in patients with heart failure","volume":"84","author":"Packer","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2026.102999_bib31","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1093\/eurheartj\/ehae917","article-title":"Anaemia predicts iron homoeostasis dysregulation and modulates the response to empagliflozin in heart failure with reduced ejection fraction: the EMPATROPISM-FE trial","volume":"46","author":"Angermann","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2026.102999_bib32","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/s44161-023-00352-5","article-title":"Empagliflozin effects on iron metabolism as a possible mechanism for improved clinical outcomes in non-diabetic patients with systolic heart failure","volume":"2","author":"Angermann","year":"2023","journal-title":"Nat Cardiovasc Res"},{"key":"10.1016\/j.jchf.2026.102999_bib33","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jacc.2024.04.055","article-title":"Effects of rapid uptitration of neurohormonal blockade on effective, sustainable decongestion and outcomes in STRONG-HF","volume":"84","author":"Biegus","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2026.102999_bib34","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1161\/CIRCULATIONAHA.122.060511","article-title":"Iron deficiency in heart failure and effect of dapagliflozin: findings from DAPA-HF","volume":"146","author":"Docherty","year":"2022","journal-title":"Circulation"}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177926000983?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177926000983?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T18:41:10Z","timestamp":1785782470000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177926000983"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2213177926000983"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2026.102999","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Empagliflozin in De Novo vs Acute Decompensated Chronic Heart Failure","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2026.102999","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"102999"}}